DKK-1 in prostate cancer diagnosis and follow up

BMC Clinical Pathology - Tập 14 - Trang 1-6 - 2014
Patrizia D’Amelio1, Ilaria Roato2, Marco Oderda3, Francesco Soria3, Andrea Zitella3, Riccardo Ferracini4, Giulio Mengozzi5, Paolo Gontero3, Giovanni Carlo Isaia1
1Gerontology Section, Department of Medical Sciences, University of Torino, Torino, Italy
2Center for Research in Experimental Medicine (CeRMS), Hospital City of Health and Science of Turin, Turin, Italy
3Urology Section, Department of Surgical Science, Hospital City of Health and Science of Turin, University of Turin, Turin, Italy
4Department of Orthopedics, Hospital City of Health and Science of Turin, Turin, Italy
5Baldi & Riberi Lab, Hospital City of Health and Science of Turin, Turin, Italy

Tóm tắt

Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa. We retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was performed in case of PCa suspicion. PSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1 was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1 performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with bone metastases, whereas PSA was not significantly different in patients with different outcomes. DKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca.

Tài liệu tham khảo

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011, 59 (1): 61-71. 10.1016/j.eururo.2010.10.039. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004, 350 (22): 2239-2246. 10.1056/NEJMoa031918. Bantis A, Grammaticos P: Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?. Hell J Nucl Med. 2012, 15 (3): 241-246. Gomceli I, Bostanci EB, Ozer I, Kemik AS, Turhan N, Tez M, Kilic S, Demiriz B, Akoglu M: A novel screening biomarker in gastric cancer: serum dickkopf-1. Hepatogastroenterology. 2012, 59 (117): 1661-1664. Jiang T, Wang S, Huang L, Zhang S: Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer. 2009, 19 (7): 1177-1181. 10.1111/IGC.0b013e31819d8b2d. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009, 55 (9): 1656-1664. 10.1373/clinchem.2009.125641. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007, 97 (7): 964-970. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H: Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007, 67 (6): 2517-2525. 10.1158/0008-5472.CAN-06-3369. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003, 349 (26): 2483-2494. 10.1056/NEJMoa030847. Manolagas SC, Almeida M: Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007, 21 (11): 2605-2614. 10.1210/me.2007-0259. Daoussis D, Andonopoulos AP: The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. Semin Arthritis Rheum. 2011, 41 (2): 170-177. 10.1016/j.semarthrit.2011.01.006. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ: Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate. 2011, 71 (6): 615-625. 10.1002/pros.21277. Menezes ME, Devine DJ, Shevde LA, Samant RS: Dickkopf1: a tumor suppressor or metastasis promoter?. Int J Cancer. 2012, 130 (7): 1477-1483. 10.1002/ijc.26449. Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar S, Hoey T, Hebrok M, Pasca di Magliano M: Canonical Wnt signaling Is required for pancreatic carcinogenesis. Cancer Res. 2013, 73 (15): 4909-4922. 10.1158/0008-5472.CAN-12-4384. Emami KH, Corey E: When prostate cancer meets bone: control by wnts. Cancer Lett. 2007, 253 (2): 170-179. 10.1016/j.canlet.2006.12.040. Guo Y, Guo W, Chen Z, Kuang G, Yang Z, Dong Z: Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma. Neoplasma. 2011, 58 (2): 110-117. 10.4149/neo_2011_02_110. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET: Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005, 65 (17): 7554-7560. Roato I, D’Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R: Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One. 2008, 3 (11): e3627-10.1371/journal.pone.0003627. Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C: Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013, 73 (9): 932-940. 10.1002/pros.22639. Ilic D, Neuberger MM, Djulbegovic M, Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev. 2013, 1: CD004720 Vasarainen H, Malmi H, Maattanen L, Ruutu M, Tammela T, Taari K, Rannikko A, Auvinen A: Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol. 2013, 52 (8): 1615-1621. 10.3109/0284186X.2013.802837. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001, 20 (3–4): 333-349. Hall CL, Keller ET: The role of Wnts in bone metastases. Cancer Metastasis Rev. 2006, 25 (4): 551-558. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET: Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008, 68 (13): 1396-1404. 10.1002/pros.20805. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, Ishikawa N, Kohno N, Ito H, Miyamoto M, Nakayama H, Miyagi Y, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y: Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010, 70 (13): 5326-5336. 10.1158/0008-5472.CAN-09-3879. Lee HS, Lee HE, Park do J, Kim HH, Kim WH, Park KU: Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta. 2012, 413 (21–22): 1753-60. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W: Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012, 13 (8): 817-826. 10.1016/S1470-2045(12)70233-4. Tung EK, Ng IO: Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. Future Oncol. 2012, 8 (12): 1525-1528. 10.2217/fon.12.147. Yao X, Jiang H, Zhang C, Wang H, Yang L, Yu Y, Yu J, Shi B, Shen Z, Gao H, Chen Z, Tian S, Lu S, Li Z, Gu J: Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer. Biomarkers. 2010, 15 (2): 128-134. 10.3109/13547500903325662. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999, 281 (17): 1591-1597. 10.1001/jama.281.17.1591. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6890/14/11/prepub
Thông tin
Thông tin xuất bản

BMC Clinical Pathology

Tập 14

1-6

Thông tin tác giả